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African horse sickness (AHS) is an arthropod-borne equinedisease caused by African horse sickness virus (AHSV) (genus
Orbivirus, family Reoviridae). The AHSV genome consists of 10
segments of double-stranded RNA (dsRNA) collectively encoding
seven structural proteins and four nonstructural proteins (1). We
report here the genome sequences of AHSV-2/Labstr/ZAF/1998/
OBP-252.1 (serotype 2), AHSV-6/Labstr/ZAF/1998/OBP-252.1
(serotype 6), AHSV-7/Labstr/ZAF/1998/OBP-252.1 (serotype 7),
and AHSV-8/Labstr/ZAF/1998/OBP-252.1 (serotype 8), which
were isolated from bottle II of the South African polyvalent AHS
attenuated live virus (ALV) vaccine (2) (Onderstepoort Biological
Products [OBP] Ltd., Onderstepoort, South Africa).
Individual serotypes were independently isolated using plaque
selection on Vero cells in the presence of heterologous antibody to
the other serotypes contained in the tetravalent vaccine, as previ-
ously described (3). Each of these viruses was then passaged on
monolayers of baby hamster kidney (BHK-21) cells, and AHSV
dsRNA was extracted, cDNA was prepared (4), and amplicons
were sequenced on an Illumina MiSeq sequencer using the Nex-
tera XT DNA sample preparation kit and 300-bp paired-end V3
Illumina chemistry, as previously described (5). Sequence reads
were analyzed using de novo assembly, followed by mapping in
Geneious 8.1.7 to obtain full-length genome sequences of the four
viruses.
The genome sequences of AHSV serotype 2 (HS82/61) and
serotype 6 (HS02/75) viruses, which are precursors of the respec-
tive AHS-ALV virus strains, are available from GenBank
(KF859996 to KF860005 and KP009741 to KP009750, respec-
tively). The pairwise nucleotide sequence identity of AHSV-2/
Labstr/ZAF/1998/OBP-252.1 and HS82/61 was 99.536%, while
that of AHSV-6/Labstr/ZAF/1998/OBP-252.1 and HS02/75 was
99.350%.
The genome sequences of the AHSV serotype 7 strain with a trun-
cated VP2 protein (AHSV7-tVP2) (6) from which AHSV-7/Labstr/
ZAF/1998/OBP-252.1 was derived are available from GenBank (ac-
cession numbers JQ742006 to JQ742015). The pairwise nucleotide
sequence identity between AHSV-7/Labstr/ZAF/1998/OBP-252.1
and AHSV7-tVP2 was 99.3% for all segments, except those encod-
ing the VP5 and nonstructural 2 (NS2) proteins, which were lower, at
77.4% and 97.9%, respectively. Analysis using RDP4.56 (7), as de-
scribed previously (5), showed that AHSV-7/Labstr/ZAF/1998/OBP-
252.1 is a reassortant (P  7.56  10-156) composed of eight segments
likely derived from AHSV7-tVP2 (accession numbers JQ742006 to
JQ742010, JQ742012, JQ742013, and JQ742015), and the other seg-
ments likely derived from HS39/63 (accession numbers KF860011
and KF860013).
The genome sequences of the AHSV serotype 8 (HS10/62)
from which AHSV-8/Labstr/ZAF/1998/OBP-252.1 was derived
are available from GenBank (accession numbers KF860026 to
KF860035). Pairwise nucleotide sequence identity between
AHSV-8/Labstr/ZAF/1998/OBP-252.1 and HS10/62 over four of
the 10 segments was 99.9%, while that for the remaining seg-
ments was between 76.8% and 97.4%. Analysis using RDP4.56 (7)
showed that AHSV-8/Labstr/ZAF/1998/OBP-252.1 is a reas-
sortant composed of four genome segments (accession numbers
KF860026 to KF860028 and KF860034) likely derived from HS10/
62, segments encoding NS1, VP5, VP7, and VP6 (accession num-
bers KM886348 to KM886350 and KM886352) likely derived
from HS30/62 (P  2.71  10-282), and the segments encoding
VP4 and NS3 likely derived from an AHSV for which whole-
genome sequence data are currently not available (P  3.72 
10-126 and 4.05  10-59, respectively).
Nucleotide sequence accession numbers. The AHSV-2/
Labstr/ZAF/1998/OBP-252.1, AHSV-6/Labstr/ZAF/1998/OBP-
252.1, AHSV-7/Labstr/ZAF/1998/OBP-252.1, and AHSV-8/
Labstr/ZAF/1998/OBP-252.1 sequences have been deposited in
GenBank under accession numbers KT715601 to KT715610,
KT715611 to KT715620, KT715621 to KT715630, and KT715631
to KT715640, respectively.
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